Skip to main content
Log in

Efficacy of anti-epileptic drugs in patients with gliomas and seizures

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited. An observational study was carried out using a database of all patients from the neuro-oncology service during the period 2000–2005, with data on seizure characteristics, therapy with AEDs, the underlying brain tumor and its treatment. A total of 140 brain tumor patients were studied of whom 23.6% had a low-grade glioma, 53.6% a high-grade glioma, and 22.8% belonged to a mixed group existing of ependymoma, meningioma, and brain metastasis. Epilepsy as the presenting sign was more frequent in low-grade vs. high-grade gliomas (69.7 vs. 52%, P = 0.087), and a total of 75.8% of patients developed seizures with low-grade and of 80.0% with high-grade gliomas. Of all 99 patients with seizures, 80.1% received valproic acid (VPA) as first choice, and either levetiracetam (LEV), carbamazepine (CBZ) or lamotrigine (LMT) as the most frequent next choice. Patients treated with a combination of VPA and LEV showed the highest percentage of responders (81.5%), with a decline in seizure frequency of more than two categories in 55.6% and seizure freedom in 59%. No correlation was found between the use of VPA and survival. A combination of VPA and LEV seems effective, if seizure control cannot be achieved by VPA alone. This indicates that adding levetiracetam may be preferable over sequential trials of AED monotherapy in treatment-resistant seizures in patients with brain tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52:717–724

    PubMed  CAS  Google Scholar 

  2. van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421–430. doi:10.1016/S1474-4422(07)70103-5

    Article  PubMed  Google Scholar 

  3. Hildebrand JF, Lecaille CF, Perennes JF, Delattre JY (2005) Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 65:212–215. doi:10.1212/01.wnl.0000168903.09277.8f

    Article  PubMed  Google Scholar 

  4. Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, Weller M (2005) Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long? Onkologie 28:391–396. doi:10.1159/000086375

    Article  PubMed  CAS  Google Scholar 

  5. Wagner GL, Wilms EB, Van Donselaar CA, Vecht C (2003) Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 12:585–586. doi:10.1016/S1059-1311(03)00096-7

    Article  PubMed  CAS  Google Scholar 

  6. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M (2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45:737–744. doi:10.1111/j.0013-9580.2004.00104.x

    Article  PubMed  CAS  Google Scholar 

  7. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC (2005) Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4:1912–1922. doi:10.1158/1535-7163.MCT-05-0184

    Article  PubMed  CAS  Google Scholar 

  8. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109. doi:10.1007/s00401-007-0243-4

    Article  PubMed  Google Scholar 

  9. Chavez-Blanco A, Perez-Plasencia C, Perez-Cardenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja-Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G, Duenas-Gonzalez A (2006) Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6(2):22–31. doi:10.1186/1475-2867-6-2

    PubMed  Google Scholar 

  10. Norden AD, Wen PY (2006) Glioma therapy in adults. Neurologist 12:279–292. doi:10.1097/01.nrl.0000250928.26044.47

    Article  PubMed  Google Scholar 

  11. Stupp RF, Mason WPFAU, van den Bent M, van den Bent MJFAU, Weller M, Weller MF, Fisher BF, Taphoorn MJFAU, Belanger K, Belanger KF, Brandes AAFAU, Marosi C, Marosi CF, Bogdahn UF, Curschmann JF, Janzer RCFAU, Ludwin S, Ludwin SKFAU, Gorlia T, Gorlia TF, Allgeier AF, Lacombe DF, Cairncross JGFAU, Eisenhauer E, Eisenhauer EFAU, Mirimanoff R, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 10:987–996. doi:10.1056/NEJMoa043330

    Google Scholar 

  12. Van der Sanden GA, Schouten LJ, van Dijck JA, van Andel JP, van der Maazen RW, Coebergh JW (2002) Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer 94:1548–1556. doi:10.1002/cncr.10357

    Article  PubMed  Google Scholar 

  13. Herman ST (2002) Epilepsy after brain insult: targeting epileptogenesis. Neurology 59:S21–S26

    PubMed  Google Scholar 

  14. Cascino GD (1990) Epilepsy and brain tumors: implications for treatment. Epilepsia 31(Suppl 3):S37–S44. doi:10.1111/j.1528-1157.1990.tb05858.x

    Article  PubMed  Google Scholar 

  15. Bootsma HP, Ricker L, Diepman L, Gehring J, Hulsman J, Lambrechts D, Leenen L, Majoie M, Schellekens A, de Krom M, Aldenkamp AP (2007) Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 10:296–303. doi:10.1016/j.yebeh.2006.11.016

    Article  PubMed  CAS  Google Scholar 

  16. Genton P, Sadzot B, Fejerman N, Peltola J, Despland PA, Steinhoff B, Rektor I, Wroe S, Maubrey MC, Vandervelden C, van Hammee G, Schlit AF, van Paesschen W (2006) Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial. Acta Neurol Scand 113:387–394. doi:10.1111/j.1600-0404.2006.00647.x

    Article  PubMed  CAS  Google Scholar 

  17. Kinirons P, McCarthy M, Doherty CP, Delanty N (2006) Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Seizure 15:387–392. doi:10.1016/j.seizure.2006.05.001

    Article  PubMed  CAS  Google Scholar 

  18. Brodie MJ, Stephen LJ (2007) Outcomes in elderly patients with newly diagnosed and treated epilepsy. Int Rev Neurobiol 81:253–263. doi:10.1016/S0074-7742(06)81016-0

    Article  PubMed  Google Scholar 

  19. Hermann DM, Kilic E, Spudich A, Kramer SD, Wunderli-Allenspach H, Bassetti CL (2006) Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 60:489–498. doi:10.1002/ana.21012

    Article  PubMed  CAS  Google Scholar 

  20. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A, Salmaggi A (2005) Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74:113–121. doi:10.1007/s11060-004-6152-7

    Article  PubMed  CAS  Google Scholar 

  21. Coupez R, Nicolas JM, Browne TR (2003) Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 44:171–178. doi:10.1046/j.1528-1157.2003.25302.x

    Article  PubMed  CAS  Google Scholar 

  22. Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2:404–409. doi:10.1016/S1474-4422(03)00435-6

    Article  PubMed  CAS  Google Scholar 

  23. Maschio M, Albani F, Baruzzi A, Zarabla A, Dinapoli L, Pace A, Pompili A, Carapella CM, Occhipinti E, Jandolo B (2006) Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 80:97–100. doi:10.1007/s11060-006-9162-9

    Article  PubMed  CAS  Google Scholar 

  24. Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78:99–102. doi:10.1007/s11060-005-9070-4

    Article  PubMed  CAS  Google Scholar 

  25. Lynam LM, Lyons MK, Drazkowski JF, Sirven JI, Noe KH, Zimmerman RS, Wilkens JA (2007) Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg 109:634–638. doi:10.1016/j.clineuro.2007.05.017

    Article  PubMed  Google Scholar 

  26. Otoul C, Arrigo C, Van Rijckevorsel K, French JA (2005) Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28:72–78. doi:10.1097/01.wnf.0000159956.87511.67

    Article  PubMed  CAS  Google Scholar 

  27. Van Rijckevorsel K, Boon PA (2001) The ‘number needed to treat’ with Levetiracetam (LEV): comparison with the other new antiepileptic drugs (AEDs). Seizure 10:235–236. doi:10.1053/seiz.2001.0497

    Article  PubMed  Google Scholar 

  28. Van den Bent MJ, Reni M, Gatta G, Vecht C (2008) Oligodendroglioma. Crit Rev Oncol Hematol 66:262–272. doi:10.1016/j.critrevonc.2007.11.007

    Article  PubMed  Google Scholar 

  29. Van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C (1998) Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry 64:581–587. doi:10.1136/jnnp.64.5.581

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

Dr. Vecht has received lectures fees from Pfizer, and an educational grant and lecture fees from UCB.

Conflict of interest statement

The other authors have nothing to disclose.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Charles J. Vecht.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Breemen, M.S.M., Rijsman, R.M., Taphoorn, M.J.B. et al. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256, 1519–1526 (2009). https://doi.org/10.1007/s00415-009-5156-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-009-5156-9

Keywords

Navigation